Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical study on Advanced Soft Tissue Sarcoma and the addition of a new version revision. The study's core details, such as the specific treatment protocols and eligibility criteria, have been deleted, which may impact the understanding of the study's scope and requirements.SummaryDifference42%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added indicating February 24, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe study has shifted from focusing on first-line treatment to previously treated patients for both Phase 1 and Phase 2 parts, and the timeline for the study has been updated with new dates. Additionally, the study's title and details have been revised to reflect these changes.SummaryDifference6%
- Check88 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.